@inproceedings{inproceedings, title  = {{Clinical fracture incidence in metastatic hormone-sensitive prostate cancer and risk-reduction following addition of zoledronic acid to androgen deprivation therapy with or without docetaxel: Long-term results from the STAMPEDE trial}},

 url = {{}},

 year = {{2023}},

 month = {{1}},

 author = {{Jones C and Sachdeva A and Murphy L and Murray M and Brown L and Brown J and Mc CE and Attard G and Parmar M and James N and Sydes MR et al}},

 volume = {{83}},

 journal = {{EUROPEAN UROLOGY}},

 note = {{Accessed on 2024/09/19}}}